Drug Approval | April 13, 2024
USFDA completes inspection of Lupin's Dabhasa facility with no observations
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The company will respond to the Warning Letter within the stipulated timelines
These observations are procedural in nature and will be responded within the stipulated time
A game changing solution for the pharmaceutical industry
The observations are procedural in nature and will be responded to within the stipulated time
The Product is expected to be the first generic approval on the market
Highly effective preservation solutions ensuring the safety and protection of personal care products
Subscribe To Our Newsletter & Stay Updated
